+ All Categories
Home > Documents > Baxter International Inc. (BAX) April 19, 2017 the global medical device market, the top 15...

Baxter International Inc. (BAX) April 19, 2017 the global medical device market, the top 15...

Date post: 28-May-2018
Category:
Upload: truongnga
View: 215 times
Download: 0 times
Share this document with a friend
26
Important disclosures appear on the last page of this report. The Henry Fund Henry B. Tippie School of Management Aric Jensen [[email protected]] Baxter International Inc. (BAX) April 19, 2017 Health Care – Equipment & Supplies Stock Rating Sell Investment Thesis Target Price $46-49 We give a Sell recommendation for Baxter International. Baxter’s stock price has been on a tear the past 12 months – up over 24% and overvalued by all of our estimates. The market has been generous due to Baxter’s ability to beat earnings throughout the separation of Baxalta and their pending acquisition of Claris Injectables. However, we feel the recent run in price has left Baxter overvalued with low levels of growth going forward. Investment Positives Baxter is a stable contract-heavy company with a history of beating earnings – you generally know what to expect. Baxter will continue to be a global leader in injectables, especially within renal therapies, and look to expand further by adding Claris Injectables. We forecast the acquisition to generate sales of $125M in 2018 and increase at a 10% CAGR through 2021. Baxter has recently strengthened their balance sheet, exemplified by their current ratio of 2.40 and debt to equity ratio of 0.34. Baxter has made apparent their desire to increase operational efficiencies and margins. Our model predicts their profit margin to increase from 10.45% in 2017 to 11.94% in 2021. Investment Negatives Sales within existing segments have only increased at 2.59% CAGR since 2013 and we forecast revenue growth at a 3.66% CAGR. This pales in comparison to Baxter’s competitors, such as Medtronic (21.2%) and Abbott Labs (8.92%). They are competing in a diversified industry where market share is hard to come by via unprotected generic drugs. Pricing pressure for the past two decades has left the industry with margins below other industries within health care, evidenced by Baxter’s 2016 adjusted profit margin of 5.7%. Henry Fund DCF $48.36 Henry Fund DDM $45.54 Relative Multiple $33.97 Price Data Current Price $52.73 52wk Range $42.22-53.54 Consensus 1yr Target $52.91 Key Statistics Market Cap (B) $28.58 Shares Outstanding (M) 541.96 Institutional Ownership 77.03% Three Year Beta 0.81 Dividend Yield 0.98% Est. 5yr Growth 14.43% Price/Earnings (TTM) 5.85 Price/Earnings (FY1) 21.52 Price/Sales (TTM) 2.81 Price/Book (mrq) 3.43 Profitability Operating Margin 12.00% Profit Margin 48.85% Return on Assets (TTM) 4.18% Return on Equity (TTM) 57.93% Earnings Estimates Year 2014 2015 2016 2017E 2018E 2019E EPS $4.61 $1.78 $9.09 $2.00 $2.20 $2.35 growth 24.6% -61.4% 410.7% -78.0% 10.0% 6.8% 12 Month Performance Company Description Baxter International is a Medical Equipment and Supply company that specializes in products related to intravenous (IV) therapies, such as pumps and administration sets, and products related to treating end-stage renal disease. In June 2015, Baxter officially separated their biopharmaceutical business as Baxalta, later bought out by Shire PLC, to focus on their Hospital Products and Renal segments. The pending acquisition of Claris Injectables Limited will help them with their goal of global generic expansion. 5.8 57.9 14.3 28.4 11.0 16.3 19.8 18.6 13.0 0 20 40 60 80 P/E ROE EV/EBITDA Data Source: FactSet BAX Industry Sector -5% 0% 5% 10% 15% 20% 25% A M J J A S O N D J F M Data Source: FactSet BAX S&P 500
Transcript

Important disclosures appear on the last page of this report.

The Henry Fund

Henry B. Tippie School of Management

Aric Jensen [[email protected]]

Baxter International Inc. (BAX) April 19, 2017

Health Care – Equipment & Supplies Stock Rating Sell

Investment Thesis Target Price $46-49 We give a Sell recommendation for Baxter International. Baxter’s stock price has been on a tear the past 12 months – up over 24% and overvalued by all of our estimates. The market has been generous due to Baxter’s ability to beat earnings throughout the separation of Baxalta and their pending acquisition of Claris Injectables. However, we feel the recent run in price has left Baxter overvalued with low levels of growth going forward.

Investment Positives • Baxter is a stable contract-heavy company with a history of beating

earnings – you generally know what to expect. • Baxter will continue to be a global leader in injectables, especially within

renal therapies, and look to expand further by adding Claris Injectables. We forecast the acquisition to generate sales of $125M in 2018 and increase at a 10% CAGR through 2021.

• Baxter has recently strengthened their balance sheet, exemplified by their current ratio of 2.40 and debt to equity ratio of 0.34.

• Baxter has made apparent their desire to increase operational efficiencies and margins. Our model predicts their profit margin to increase from 10.45% in 2017 to 11.94% in 2021.

Investment Negatives • Sales within existing segments have only increased at 2.59% CAGR since

2013 and we forecast revenue growth at a 3.66% CAGR. This pales in comparison to Baxter’s competitors, such as Medtronic (21.2%) and Abbott Labs (8.92%).

• They are competing in a diversified industry where market share is hard to come by via unprotected generic drugs.

• Pricing pressure for the past two decades has left the industry with margins below other industries within health care, evidenced by Baxter’s 2016 adjusted profit margin of 5.7%.

Henry Fund DCF $48.36 Henry Fund DDM $45.54 Relative Multiple $33.97 Price Data Current Price $52.73 52wk Range $42.22-53.54 Consensus 1yr Target $52.91 Key Statistics Market Cap (B) $28.58 Shares Outstanding (M) 541.96 Institutional Ownership 77.03% Three Year Beta 0.81 Dividend Yield 0.98% Est. 5yr Growth 14.43% Price/Earnings (TTM) 5.85 Price/Earnings (FY1) 21.52 Price/Sales (TTM) 2.81 Price/Book (mrq) 3.43 Profitability Operating Margin 12.00% Profit Margin 48.85% Return on Assets (TTM) 4.18% Return on Equity (TTM) 57.93%

Earnings Estimates Year 2014 2015 2016 2017E 2018E 2019E

EPS $4.61 $1.78 $9.09 $2.00 $2.20 $2.35

growth 24.6% -61.4% 410.7% -78.0% 10.0% 6.8%

12 Month Performance Company Description

Baxter International is a Medical Equipment and Supply company that specializes in products related to intravenous (IV) therapies, such as pumps and administration sets, and products related to treating end-stage renal disease. In June 2015, Baxter officially separated their biopharmaceutical business as Baxalta, later bought out by Shire PLC, to focus on their Hospital Products and Renal segments. The pending acquisition of Claris Injectables Limited will help them with their goal of global generic expansion.

5.8

57.9

14.3

28.4

11.0 16.319.8 18.6

13.00

20

40

60

80

P/E ROE EV/EBITDA

Data Source: FactSet

BAX Industry Sector

-5%

0%

5%

10%

15%

20%

25%

A M J J A S O N D J F M

Data Source: FactSet

BAX S&P 500

Page 2

EXECUTIVE SUMMARY

We give a Sell recommendation for Baxter International. Baxter stock price has outpaced the S&P 500 over the past year despite going through the separation of Baxalta and their pending acquisition of Claris Injectables. While they are consistent in beating earnings estimates, they have not adequately grown their existing segments enough – nor is the pending acquisition grand enough – to warrant their current price.

Baxter’s new acquisition will help them achieve their strategy of global growth in generic injectables, but we do not envision the new injectables beating our lofty forecast of 10% growth after 2018. The medical equipment and supply industry is extremely diversified, which makes generic sales very competitive. Becton, Dickinson and Company has doubled U.S. sales and nearly doubled medical device sales since 2014 and Abbott Laboratories has grown international generic drug sales at a 11.25% CAGR since 2014. If they can carry forward that momentum into Baxter’s path, it would slow growth even further moving forward.

COMPANY DESCRIPTION

Baxter International, incorporated in 1931, has a long history in medical equipment and supplies. Based out of Deerfield, IL, Baxter manufactures in over 20 countries and sells their products and services in over 100 countries. Baxter’s customers are mainly hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and individual patients. Baxter operates in two main segments, Hospital Products and Renal.1

Data Source: BAX 2016 10-K

Hospital Products

Hospital Products is the highest sales segment, with $6.3B in sales in 2016. This was an increase of 2.09% from 2015 after experiencing a decrease in sales of 5.62% from the previous year. This segment is further split into four sub-segments.1

Fluid Systems

Products within Fluid Systems consist of intravenous (IV) therapies, infusion pumps, and administration sets. Fluid Systems sales increased 9.21% to $2.3B in 2016. This was driven by a sales increase of their SIGMA SPECTRUM pump and IV solutions.1 Our forecast expects the greatest growth going forward in the Fluid Systems sub-segment. For the five-year forecast period, we estimate sales to grow at 4.01% CAGR. This is due to their focus on operational efficiency and synergies from the acquisition of Claris Injectables, which is discussed in the next section.

Integrated Pharmacy Solutions

This sub-segment consists of premixed and oncology drugs, nutrition products, and pharmacy compounding services. Revenue has experienced decreases in each of the past two years, totaling -9.06% in 2015 and -2.26% to $2.2B in 2016. Most of these decreases are attributed to lower U.S. sales of their generic oncology drug cyclophosphamide due to a competitor entering the market in 2014. Cyclophosphamide sales were $450M in 2014, $270M in 2015, and $210M in 2016. We expect sales to decline again in 2017 before stabilizing in 2018.

The drops in cyclophosphamide sales were partially offset by increased revenue from pharmacy compounding services and nutritional therapies in each of the last two years. Revenue in 2015 was also aided by government orders of poison/overdose antidote PROTOPAM, however these orders did not reoccur in 2016.1 Overall, we expect sales growth at a 3.37% CAGR through 2021.

Surgical Care

The Surgical Care sub-segment consists of inhaled anesthesia products and biological products and medical devices that are used in surgery related to hemostasis, tissue sealing, and adhesion prevention. Sales within Surgical Care have been relatively flat near $1.3B since 2013, seeing growth at a low 0.36% CAGR.1 We expect

62%

38%

2016 Sales by Segment (Total $10.2B)

Hospital Products

Renal

Page 3

sales within this segment to increase to a CAGR of 1.6% due to Baxter’s global expansion efforts.

Other

The Other sub-segment consists of revenue related to products that Baxter manufactures for its pharmaceutical partners. Other revenue has been slowly slipping since 2013 as Baxter has experienced reduced demand for these services and one partner electing to self-manufacture products previously contracted to Baxter. From 2013 to 2016, other revenue decreased to $442M at 4.72% CAGR.1 We have forecasted other revenue to increase at a 2.5% CAGR for the next five years.

Data Source: BAX 2016 10-K

Renal

The Renal segment consists of products that treat end-stage renal disease, including peritoneal dialysis (PD), hemodialysis (HD), and continuous renal replacement therapy (CRRT). It is estimated that 10% of people worldwide suffer from chronic kidney disease (CKD) and that over 1 million people die annually from untreated kidney failure. In the U.S. alone, spending on renal treatment could exceed $48B.2

Baxter experienced Renal sales of $3.86B in 2016, up 1.74% from $3.79B in 2015. The increase is attributed to growth within the PD and CRRT businesses.1 Our model forecasts Renal to attain a sales growth rate of 3.69% CAGR. This is due to their dedication towards reaching a greater number of patients globally.

Company Analysis

Baxter is amid a transition period that started with the separation of their biopharmaceutical business, Baxalta, in 2015. They view the separation as a vital step towards

optimizing the Hospital Products and Renal segments. Baxter aims to further solidify these segments with the potential launch of more than 100 products by 2020.1 They brought to market 20 such launches in 2016. This included the introduction of Numeta G13E, which is “the only triple-chamber commercially prepared parenteral nutrition system approved for vulnerable neonatal patients.”3 It should be noted that this includes new products, enhancing current products, and expansion into new geographical markets.1

RECENT DEVELOPMENTS

Earnings

In 2016, Baxter came in above estimates all four quarters with average earnings surprise percentage of 18.3%.4 This is greatly tied to much of Baxter’s revenues stemming from contracts with their customers and keeping guidance achievable. The 2017 EPS estimate from our model is $2.00, which is below guidance of $2.10-$2.18 for adjusted EPS and above GAAP EPS of $1.52-$1.67.2 They are due to release Q1 earnings on April 26 with an EPS estimate of $0.52.

Agreement to Acquire Claris Injectables

In December 2016, Baxter agreed to purchase Claris Injectables Limited for $625M in cash. This deal is expected to close in the second half of 2017. Currently, Claris Injectables is a wholly owned subsidiary of Claris Lifesciences Limited, which is based out of India. The newly acquired business was expected to generate over $100M in revenue in 2016 and is viewed as a strategic acquisition to enhance Baxter’s generic injectable portfolio as it looks to expand globally in emerging markets. Since the deal is supposed to be finalized in late 2017, we forecasted $125M in sales for 2018 and growth at a 10% CAGR through 2021.5

Separation of Baxalta

In July 2015, Baxter leadership decided it would be better for the distinctly different businesses to forge their own respective paths. Immediately upon separation, Baxalta entered the S&P 500 and Baxter dropped out.6 This was a good opportunity to separate the slow stable contract-growth side of Baxter from the risk-reward biopharma side of Baxalta.

36%

36%

21%

7%

2016 Sales in Hospital Products ($6.3B)

Fluid Systems

Integrated PharmacySolutionsSurgical Care

Other

Page 4

Baxter retained a 19.5% stake in Baxalta into 2016. They disposed of the stake through a combination of debt-for-equity and equity-for-equity exchanges and by contributing to their U.S. pension plan. Baxter openly recognizes a possible tax liability due to the shares transaction.1

INDUSTRY TRENDS

Growth Amid Diversification

Among the global medical device market, the top 15 companies owned roughly 43.5% of the market share as of 2014. The biggest was Johnson & Johnson, with a 7.3% market share.

While the expected market growth through 2020 is a 4.1% CAGR, Baxter’s estimated growth, per Evaluate Group, from 2014-2020 is a 2.7% CAGR. Our model optimistically forecasts a 3.66% CAGR in sales through 2021.

Pricing Pressure

For nearly two decades, the medical device market has experienced unrelenting pressure on their prices. The main way for hospitals to controls prices is to spend less on capital expenditures. Baxter and their competitors are greatly dependent on capital expenditure budgets of hospitals and reimbursement from programs such as Medicare.

This was further enforced from 2013 to 2015 by the Patient Protection and Affordable Care Act (ACA). Within the first year, the 2.3% excise tax levied on medical devices was estimated to cause a loss of 165,000 jobs directly and indirectly. As well, 30.6% of respondents in a survey administered by AdvaMed reported a decrease in R&D spending due to the tax and almost 10% percent reported moving jobs abroad.7

Enduring controversy, a two-year moratorium on the excise tax went into effect for calendar years 2016 and 2017. While this did not cause U.S. medical devices companies to instantly hyperinflate their prices, it has allowed them the freedom to spend more on R&D and global expansion. We have not included any excise tax effects into our model because we see the moratorium being extended or repeal of this tax as highly likely.

Increase in M&A Activity

The pricing pressures have led bigger medical device companies to look towards economies of scale and attempt to offer comprehensive solutions to patients. This has led to an explosion of M&A activity since the middle of 2013.

Page 5

The largest acquisition from July 2015 to June 2016 was that of Abbott Laboratories purchasing St. Jude Medical for $25B. In total, a record 213 deals happened in that year, with an aggregate deal value of nearly $80B.8 With their previously discussed acquisition of Claris Injectables, Baxter aims to grow via the same method and have stated that they will continue to monitor for accretive acquisitions going forward.

MARKETS AND COMPETITION

There are two forces that exert power on the Equipment & Supplies Industry. Due to the diversification, rivalry within the industry is extremely high. This is partially mitigated by the patents and niches that are observed, but exists nonetheless. The second force that impacts pricing within the industry is that of buyer power. This has to do with the industry being dependent on hospital capital expenditures and the pressure from government and insurance companies for the industry to keep prices at an affordable level.

Peer Comparisons

Becton, Dickinson and Company (BDX)

Based out of New Jersey with over 100 years in medical equipment, BDX is arguably Baxter’s most direct competitor. BDX has two business segments: BD Medical and BD Life Sciences.

The Medical segment, with 2016 sales of $8.7B, offers products related to intravenous medication delivery. These products include syringes, needles, and infusion pumps focusing on the treatment of diabetes.

BDX has experienced sales growth at 21.6% CAGR since 2014. This has been driven by U.S. sales within their Medical segment.9

BDX has performed well in the market over the last year, posting returns only beaten by Baxter among the peers. BDX would appear overvalued when looking at their P/B ratio of 5.17, which is highest of the group. When comparing BDX to BAX, it seems BDX has spent less on R&D and SG&A in exchange for a higher profit margin.

Abbott Laboratories (ABT)

Abbott Labs, based out of Illinois, is yet another player with over 100 years in medical equipment. With the separation of their major pharmaceutical business as AbbVie in 2013, they have since postured as a dominant force in nutritional and medical devices. Abbott’s products exist within four segments: Established Pharmaceuticals, Nutritionals, Diagnostics, and Vascular.

The Established Pharmaceuticals segment consists of generic drugs sold outside the U.S. in the areas of gastroenterology, women’s health, cardiovascular and metabolic products, pain and central nervous system products, and respiratory drugs and vaccines. This segment has been the highest growth segment for Abbott since 2014 with a CAGR of 11.25%.

In January 2017, Abbott completed the acquisition of St. Jude Medical for $25B in cash and common shares. This will considerably enhance the heart and medical device sales for Abbott.10,11 Abbott’s P/E ratio (46.78) suggests that the market is excited about the growth opportunities this could bring. However, they seem adequately priced when viewing P/S and P/B. One statistic to note is their low profit margin relative to the peers of 5.1%. Abbott has also shown the most volatility and least return in stock price among the peers over the past year.

Revenue ($M) R&D/Sales SG&A/Sales Profit Margin

JNJ 71,890 12.7% 27.7% 23.0%

MDT* 28,833 7.7% 32.8% 12.3%

ABT 20,853 6.8% 32.0% 5.1%

BDX 12,483 6.6% 24.1% 7.8%

BAX 10,163 6.4% 27.0% 5.7%

*FYE 29 Apr 16 Data Source: FactSet

Revenue (millions) 2014 2015 2016 CAGR

Medical 4,573 6,460 8,654 37.6%

U.S. Total Sales 3,417 5,069 6,893 42.0%

Data Source: BDX 2016 10-K

Revenue (millions) 2014 2015 2016 CAGR

Established Pharmaceuticals 3,118 3,720 3,859 11.25%

Nutritionals 6,953 6,975 6,899 -0.39%

Diagnostics 4,721 4,646 4,813 0.97%

Vascular 2,986 2,792 2,896 -1.52%

Other 2,469 2,272 2,386 -1.70%

Total 20,247 20,405 20,853 1.49%

Data Source: ABT 2016 10-K

Page 6

Data Source: FactSet

Medtronic (MDT)

Based out of Ireland, Medtronic had sales of $28.8B for fiscal year ending April 29, 2016. This was a 42.3% increase from the previous fiscal year, due mostly to the acquisition of Covidien in January 2015. The 2015 revenue from Covidien was reported separately from pre-existing operations, but serves to boost their Minimally Invasive Therapies segment. Medtronic’s business consists of three other segments: Cardiac and Vascular, Restorative Therapies, and Diabetes.

Medtronic boasts the second largest market cap among the peers and the price-to-book ratio points towards them being undervalued. The P/E and P/S ratios are in line with the peers outside that of Baxter’s. Medtronic achieved a profit margin much higher than the pure-play peers at 12.3%, while spending the most on SG&A at 32.8% and most on R&D among pure-play peers at 7.7%.

Within the Diabetes segment, which is the smallest revenue generating segment, Medtronic develops and manufactures products related to insulin pump therapy, glucose monitoring, and software for therapy management. Given the nature of Medtronic’s other segments and Diabetes achieving the slowest sales growth of the segments at 6%, do not be surprised to see a possible divestiture of this segment in the future. This would effectively remove Medtronic as a pure competitor of Baxter, as Baxter has shifted their focus to international injectable sales.12

Johnson & Johnson (JNJ)

Based out of New Jersey, JNJ is easily the goliath of the medical device industry, with a market cap of over $203B and 2016 sales of $71.9B. JNJ does business in three segments: Consumer, Pharmaceutical, and Medical Devices.

Revenue within the Medical Devices segment totaled $25.1B in 2016.13 JNJ also boasts the highest price-to-book and price-to-sales ratios, and profit margin among the peers at 4.59, 4.68, and 23.0%. JNJ’s profit margin is an outlier that can be attributed to their Pharmaceutical segment that consists of premium-priced patented drugs. Their P/S ratio is most likely a reflection of their commitment to R&D spending and delivering results.

ECONOMIC OUTLOOK

Health Expenditures and GDP

Medical equipment and supplies sales is directly tied to health care spending. All estimates lead to this spending to keep increasing, at minimum, the same rate as GDP in the future.

-15%

-10%

-5%

0%

5%

10%

15%

20%

25%

A M J J A S O N D J F M

BAX ABT PFE BDX MDT Market Cap ($B) P/E P/S P/B

PFE 203.07 29.07 3.84 3.48

MDT 110.02 28.37 3.75 2.23

ABT 75.74 46.78 3.63 3.14

BDX 39.18 30.64 3.16 5.17

BAX 28.61 5.86 2.82 3.44

Data Source: Yahoo Finance

Page 7

This is a good sign for stable long-term growth within this industry and part of the reason we have forecasted a CV growth rate of 2.5% for Baxter.

The correlation of health care spending to GDP looks good for Baxter considering their ongoing efforts to expand globally, as emerging markets and developing economies are forecasted to see 4.6% GDP growth in 2017.

Health Care Reform

At this point it seems likely that the 2.3% medical device excise tax will be either repealed or have the moratorium extended beyond 2017, therefore we have not modeled the excise tax into our forecast. The American Health Care Act of 2017 (AHCA) that was proposed by President Trump set out to permanently repeal the excise tax. The failure of the AHCA to get passed has led some to question the future of the moratorium. Scott Whitaker, CEO of AdvaMed, noted that repeal continues to have “broad partisan support.” With Republicans controlling both the House and the Senate and set on tax reform, there is a

good chance this tax is not a factor through President Trump’s term.14

Population Demographics

Population growth may be not be as rapid as it once was, but advances in health care have increased expected lifespans. This has led to a shift in the age demographic of the population.

In 1980, less than 12% of the U.S. population was above 65. That number is expected to be 16% by 2020. As this percentage increases, health care spending will increase and lead to more capital spending on medical devices and injectables.

Emerging Market Standards of Care

Another trend that favors the medical device industry is emerging markets’ access to advanced health care. Baxter aims to take advantage of this increase in spending through its acquisition of Claris Injectables and its existing presence in India and easier access to the rest of Asia.

Page 8

Data Source: Siemens Healthcare

CATALYSTS FOR GROWTH

Aging Population

As described in the previous section, the U.S. population is aging. As emerging markets continue to gain access to improved health care, the global population will follow this trend. This bodes well for the medical device industry as the number of chronic conditions and health care spending increases the older a person gets.

Data Source: CMS Chronic Conditions Among Medicare

Beneficiaries Chartbook 2012 Edition

Worldwide, it is estimated that one out of five men and one out of four women aged 65-74 have chronic kidney disease (CKD).3 This bodes well for Baxter’s Renal segment moving forward.

Access to Health Insurance

While the ACA has slowed per capita health care spending growth, the increase in percentage of people insured will

keep spending closely tied to GDP. This should help hospitals to budget capital expenditures and possibly help companies like Baxter secure more contracts.

INVESTMENT POSITIVES

• Baxter is a stable contract-heavy company with a history of beating earnings – you generally know what to expect.

• Baxter will continue to be a global leader in injectables, especially within renal therapies, and look to expand further by adding Claris Injectables.

• Baxter has a strong balance sheet, exemplified by their current ratio of 2.40 and debt to equity ratio of 0.34.

• Baxter has made apparent their desire to increase operational efficiencies and margins as they transition to a value stock.

INVESTMENT NEGATIVES

• Baxter is forecasted to lose market share to competitors through 2020.

• They are competing in a diversified industry where market share is hard to come by via generic drugs.

• Pricing pressure for the past two decades has left the industry with margins below other industries within health care.

Page 9

VALUATION

In the valuation model, we used a 3-year raw Beta of 0.81. Using a Henry Fund consensus equity risk premium of 4.80% and a risk-free rate of 2.84% (30-year treasury yield), a cost of equity of 6.73% was calculated. Then, using a pre-tax cost debt of 4.32%, which correlates to their existing 30-year senior notes, a WACC of 6.39% was calculated.

Revenue Growth

We have forecasted overall revenue growth at 3.66% CAGR with a continuing growth value of 2.5%.

Data Source: BAX 2016 10-K and Henry Fund Estimates

Baxter’s portfolio growth going forward is forecasted to be balanced with Fluid Systems, Renal, and Integrated Pharmacy Solutions leading the growth with respective 5-year CAGRs of 4.01%, 3.69%, and 3.37%. These projections are attributed to Baxter’s international growth strategy with added growth to the Fluid Systems due to the synergies from the acquisition of Claris Injectables.

Operating Expenses Assumptions

Baxter has stated operational efficiency as a top priority. We have forecasted cost of goods sold to decrease and amortization to decrease in line with guidance from Baxter through the forecast period. Baxter has been employing accelerated depreciation and added business optimization expenses since the separation of Baxalta. Therefore, we have also forecasted capital expenditures to decrease from the previous five-year average of 11.7% to 7% in 2017 and 3% by 2021. This also effectively causes depreciation to decrease from 4.20% to 3.94% during that same time. We are holding SG&A and R&D expenses constant as a percentage of sales at 25% and 6%, respectively. These are

below historical averages to further reflect their intent to increase margins. We feel it is unrealistic to decrease these further considering their objective to innovate and focus on global expansion. The 2017 estimates for these two expenses are slightly above analyst estimates of $574M (5.6%) for R&D and $2,432M (23.8%) for SG&A.10

Data Source: BAX 2016 10-K and Henry Fund Estimates

Margin Forecasts

Baxter’s focus on decreasing operating expenses will serve to slightly increase their margins going forward. When viewing the chart below, the spike in profit margin is due to the net realized gains on the retained shares transaction. These gains were disbursed to shareholders, which deems the spike as non-consequential. When adjusted by removing the retained shares gain, a profit margin of 5.7% is calculated.

Data Source: BAX 2016 10-K and Henry Fund Estimates

9,000

10,000

11,000

12,000

13,000

2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Projected Revenue (in millions)0%

10%

20%

30%

40%

50%

60%

Operating Expenses as % of Sales

COGS DepreciationAmortization Marketing & AdminR&D

0%

10%

20%

30%

40%

50%

60%

2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Projected Margins

Gross Margin EBIT Margin Profit Margin

Page 10

Model Results

Per the results of our DCF model ($48.36), Baxter is overvalued considering the current stock price of $52.79. This would become further overvalued if we were to adjust our estimates for short-term and long-term growth down towards analysts’ estimates. Our 5-year sales CAGR of 3.66% is optimistic relative to analysts’ consensus of 2.87% CAGR.10 As well, the Henry Fund model accounts for CV NOPLAT growth of 2.5%.

Baxter has had trouble paying stable dividends since the separation of Baxalta. If the DDM were to be used with 10% yearly dividend growth, Baxter would be overvalued compared to the DDM price of $45.54. Given the Relative P/E model price of $33.97, Baxter would appear to be even further overvalued. The relative model can be further discounted when considering that Baxter reported an inflated 2016 EPS of $9.09. This was caused by the retained shares transaction from the sale of Baxalta. When removing this transaction from the income statement, it leaves an adjusted EPS of $1.06.

Forecast Versus Consensus

Due to our model being optimistic for both short-term and long-term growth, a lot of the assumptions can be detached from the sensitivity of our Sell rating. However, there is one assumption that our model is sensitive to, which is the tax rate. This has a lot to do with the fact that over 58% of their sales are international. Upon performing sensitivity analysis, decreasing our assumed marginal tax rate of 19% to 15% would indicate a DCF price of $52.05 – meaning fair value and possibly a hold rating.

Consensus for a total of 16 analysts has a Hold rating and a target price of $52.91.10 This comes in above our target price of $46-49 and DCF value of $48.36. However, this should come as no surprise considering the historic tendency of analysts to either be optimistic about the covered company or quit covering the company. The most important factors are the analysts’ Hold rating in combination with a forecasted price within 1% of the current price and the fact that the price is up nearly 25% in the past 12 months. However, due to Baxter’s consistency in beatings earnings estimates, it is probably best to hold until after the next earnings release at the end of April 2017.

KEYS TO MONITOR

• Due to 58% of Baxter’s revenue coming from international sales, currency exchange rates can easily erase a 2% gain in those sales.

• Investors will also want to keep an eye out for first quarter earnings and revised guidance being released at the end of April 2017. Their consistency in beating earnings could worry investors if missing earnings is in combination with lowered guidance for the rest of the year. This could drop the market price of Baxter below the Henry Fund target price.

• Currently, the medical device excise tax is set to go back into effect on January 1, 2018. This would lead to the forecast being revised and lowering the target price.

• As stated, the most difficult assumption in our model was the forecasted tax rate. While it is unlikely for Baxter to have a long-term tax rate below 15% going forward, keep an eye out.

IMPORTANT DISCLAIMER

Henry Fund reports are created by student enrolled in the Applied Securities Management (Henry Fund) program at the University of Iowa’s Tippie School of Management. These reports are intended to provide potential employers and other interested parties an example of the analytical skills, investment knowledge, and communication abilities of Henry Fund students. Henry Fund analysts are not registered investment advisors, brokers or officially licensed financial professionals. The investment opinion contained in this report does not represent an offer or solicitation to buy or sell any of the aforementioned securities. Unless otherwise noted, facts and figures included in this report are from publicly available sources. This report is not a complete compilation of data, and its accuracy is not guaranteed. From time to time, the University of Iowa, its faculty, staff, students, or the Henry Fund may hold a financial interest in the companies mentioned in this report.

Page 11

REFERENCES

1 BAX 2016 10-K 2 "Global Facts: About Kidney Disease." The National Kidney

Foundation. N.p., 11 Mar. 2015. Web. 19 Apr. 2017. 3 "Baxter Reports 2016 Fourth-Quarter and Full-Year Results."

TheStreet. TheStreet, 01 Feb. 2017. Web. 08 Apr. 2017. 4 BAX, Yahoo Finance 5 "BRIEF-Baxter International to Buy Claris Injectables Limited."

Reuters. Thomson Reuters, 15 Dec. 2016. Web. 08 Apr. 2017. 6 "Baxter, Baxalta Highlight Business Strategies." CenterWatch

News Online. 21 May 2015. Web. 08 Apr. 2017. 7 "In Focus: The New Medical Device Excise Tax." AORN Journal

97.2 (2013). AdvaMed. Web. 8 Apr. 2017.

8 "Medical Technology Report 2016." Pulse of the Industry (2016). Ernst & Young. Web. 8 Apr. 2017.

9 BDX 2016 10-K 10 FactSet 11 ABT 2016 10-K 12 MDT 2016 10-K 13 JNJ 2016 10-K 14 Fenske, Sean. "The Tax That Wouldn't Die." Your Online

Source for Medical Device Product Information - Medical Product Outsourcing. MPO Magazine, 3 Apr. 2017. Web. 08 Apr. 2017.

Baxter International Inc.

Revenue Decomposition

Fiscal Years Ending Dec. 31 2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Hospital Products:

Fluid systems 2,129 2,106 2,300 2,320 2,420 2,530 2,700 2,800

Integrated pharmacy solutions 2,535 2,297 2,245 2,200 2,260 2,340 2,520 2,650

Surgical care 1,373 1,323 1,321 1,330 1,370 1,410 1,420 1,430

Other 510 453 442 460 470 480 490 500

Total Hospital Products 6,547 6,179 6,308 6,310 6,520 6,760 7,130 7,380

Total Renal Sales 4,172 3,789 3,855 3,890 4,080 4,230 4,390 4,620

Total BioScience Sales - - - - - - - -

Acquired Injectables Sales - - - - 125 138 151 166

Total Sales 10,719 9,968 10,163 10,200 10,725 11,128 11,671 12,166

Revenue Decomposition (% of sales)

Hospital Products:

Fluid systems 19.86% 21.13% 22.63% 22.75% 22.62% 22.79% 23.19% 23.08%

Integrated pharmacy solutions 23.65% 23.04% 22.09% 21.57% 21.12% 21.08% 21.65% 21.84%

Surgical care 12.81% 13.27% 13.00% 13.04% 12.80% 12.70% 12.20% 11.79%

Other 4.76% 4.54% 4.35% 4.51% 4.39% 4.32% 4.21% 4.12%

Total Hospital Products 61.08% 61.99% 62.07% 61.86% 60.93% 60.90% 61.25% 60.83%

Total Renal Sales 38.92% 38.01% 37.93% 38.14% 38.13% 38.11% 37.71% 38.08%

Total BioScience Sales - - - - - - - -

Acquired Injectables Sales - - - 0.00% 0.93% 0.99% 1.04% 1.10%

Total Hospital Products Growth 3.53% -5.62% 2.09% 0.03% 3.33% 3.68% 5.47% 3.51%

Total Renal Sales Growth 35.06% -9.18% 1.74% 0.91% 4.88% 3.68% 3.78% 5.24%

Injectable Sales Growth - - - - - 10.00% 10.00% 10.00%

Total Product Sales Growth 13.87% -7.01% 1.96% 0.36% 5.15% 3.75% 4.89% 4.24%

Revenue Decomposition by Region

United States 3,999 4,001 4,259 4,233 4,397 4,507 4,669 4,806

International 6,720 5,967 5,904 5,967 6,328 6,621 7,003 7,361

Total Product Sales 10,719 9,968 10,163 10,200 10,725 11,128 11,671 12,166

Revenue Decomposition by Region

United States 37.31% 40.14% 41.91% 41.50% 41.00% 40.50% 40.00% 39.50%

International 62.69% 59.86% 58.09% 58.50% 59.00% 59.50% 60.00% 60.50%

United States Sales Growth 11.58% 0.05% 6.45% -0.61% 3.88% 2.49% 3.59% 2.94%

International Sales Growth 15.29% -11.21% -1.06% 1.07% 6.05% 4.63% 5.77% 5.11%

Total Product Sales 100% 100% 100% 100% 100% 100% 100% 100%

Baxter International Inc.

Income Statement

Fiscal Years Ending Dec. 31 2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Net sales 10,719 9,968 10,163 10,200 10,725 11,128 11,671 12,166

Cost of goods sold 5,133 5,063 5,253 5,100 5,336 5,508 5,748 5,962

Depreciation 613 597 632 429 457 487 494 479

Amortization 392 162 168 138 125 121 118 114

Gross margin 4,581 4,146 4,110 4,533 4,807 5,012 5,311 5,612

Marketing & administrative expenses 3,315 3,094 2,739 2,550 2,681 2,782 2,918 3,042

Research & development expenses 610 603 647 612 644 668 700 730

Operating income (loss) 656 449 724 1,371 1,482 1,562 1,693 1,840

Interest expense (167) (146) (89) (120) (120) (120) (120) (120)

Interest income 22 20 23 23 23 23 23 23

Gain related to the reduction of contingent payment liabilities - - - - - - - -

Foreign exchange 8 113 28 32 33 34 36 38

Gain (loss) on debt extinguishment - (130) (153) - - - - -

Net realized gains on retained shares transaction - - 4,387 - - - - -

Gain on litigation settlement - 52 - - - - - -

Gain on sale of investments & other assets 20 38 3 - - - - -

Other income (expense) (49) 32 31 10 11 11 12 12

Income (loss) from continuing operations before income taxes 490 428 4,954 1,316 1,429 1,511 1,645 1,793

Income tax expense 33 35 (12) 250 271 287 312 341

Income (loss) from continuing operations 457 393 4,966 1,066 1,158 1,224 1,332 1,453

Income (loss) from discontinued operations, net of tax 2,040 575 (1) - - - - -

Net income (loss) 2,497 968 4,965 1,066 1,158 1,224 1,332 1,453

Year end shares outstanding 542 548 540 533 527 521 515 510

Net income (loss) per share - basic 4.61 1.78 9.09 2.00 2.20 2.35 2.58 2.85

Cash dividends declared per common share 2.05 1.27 0.51 0.56 0.61 0.67 0.74 0.81

Baxter International Inc.

Balance Sheet

Fiscal Years Ending Dec. 31 2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Assets:

Cash & equivalents 2,925 2,213 2,801 2,793 2,991 3,425 4,115 4,510

Accounts & other current receivables, net 1,884 1,731 1,691 1,683 1,770 1,836 1,926 2,007

Inventories 1,577 1,604 1,430 1,479 1,555 1,613 1,692 1,764

Short-term deferred income taxes 27 302 147 155 168 178 194 211

Prepaid valuation added taxes 71 118 114 114 114 114 114 114

Other prepaid expenses 380 435 341 357 375 389 408 426

Investment in Baxalta common stock - 5,148 - - - - - -

Current assets held for disposition 3,298 245 50 50 50 50 50 50

Total current assets 10,162 11,796 6,574 6,631 7,023 7,606 8,499 9,082

Property, plant & equipment, net 4,434 4,386 4,289 4,574 4,867 4,937 4,794 4,679

Goodwill 2,927 2,687 2,595 3,134 3,134 3,134 3,134 3,134

Other intangible assets, net 1,620 1,349 1,111 973 848 727 609 495

Deferred income taxes 531 354 629 521 565 598 651 710

Other long-term receivables 84 176 181 182 191 198 208 217

Non-current assets held for disposition 6,065 - - - - - - -

Other long-term assets 315 214 167 168 176 183 192 200

Total assets 26,138 20,962 15,546 16,182 16,805 17,383 18,086 18,517

Liabilities:

Short-term debt 913 1,775 - - - - - -

Current maturities of long-term debt & lease obligations 785 810 3 3 3 3 297 403

Accounts payable, principally trade 677 716 791 765 804 835 875 912

Income taxes payable 336 453 126 203 221 233 254 277

Deferred income taxes - - - - - - - -

Common stock dividends payable 363 137 70 75 81 89 96 105

Employee compensation & withholdings 485 481 542 510 536 556 584 608

Property, payroll & certain other taxes 184 166 143 153 161 167 175 182

Infusion pump reserves 145 52 - - - - - -

Business optimization reserves 89 98 153 153 153 153 153 153

Accrued rebates 174 192 206 204 215 223 233 243

Seperation-related reserves - 190 46 46 46 46 46 46

Other accounts payable & accrued liabilities 560 634 661 663 697 723 759 791

Current liabilites held for disposition 1,326 46 3 3 3 3 3 3

Total current liabilities 6,037 5,750 2,744 2,778 2,920 3,030 3,475 3,724

Long-term debt & lease obligations, net 7,331 3,922 2,779 2,776 2,773 2,770 2,473 2,070

Pension & other employee benefits 2,198 2,041 1,492 1,785 1,877 1,947 2,042 2,129

Deferred tax liabilities 168 195 93 170 184 195 212 231

Litigation reserves 32 24 19 19 19 19 19 19

Infusion pump reserves - - - - - - - -

Business optimization reserves 38 18 11 11 11 11 11 11

Contingent payment liabilities 51 20 15 15 15 15 15 15

Non-current liabilities held for disposition 1,677 - - - - - - -

Other long-term liabilities 450 127 113 102 107 111 117 122

Total liabilities 17,982 12,097 7,266 7,656 7,907 8,099 8,365 8,321

Shareholders' Equity:

Common stock & additional contributed capital 6,536 6,585 6,641 6,832 7,022 7,213 7,403 7,594

Common stock in treasury, at cost (7,993) (7,646) (7,995) (8,620) (9,270) (9,945) (10,645) (11,395)

Retained earnings 13,227 9,683 14,200 14,880 15,712 16,582 17,529 18,562

Currency translation adjustments (CTA) (2,323) (3,191) (3,438) (3,438) (3,438) (3,438) (3,438) (3,438)

Pension & other employee benefits (1,427) (1,064) (1,161) (1,161) (1,161) (1,161) (1,161) (1,161)

Hedging activities 34 7 3 3 3 3 3 3

Available-for-sale securities - 4,472 40 40 40 40 40 40

Other accumulated other comprehensive income (loss) 66 - - - - - - -

Accumulated other comprehensive income (loss) (3,650) 224 (4,556) (4,556) (4,556) (4,556) (4,556) (4,556)

Total Baxter International Inc. shareholders' equity 8,120 8,846 8,290 8,536 8,908 9,294 9,731 10,205

Noncontrolling interests 36 19 (10) (10) (10) (10) (10) (10)

Total equity 8,156 8,865 8,280 8,526 8,898 9,284 9,721 10,195

Total liabilities and shareholders' equity 26,138 20,962 15,546 16,182 16,805 17,383 18,086 18,517

Baxter International Inc.

Cash Flow Statement

Fiscal Years Ending Dec. 31 2012 2013 2014 2015 2016

Net income (loss) 2,326 2,012 2,497 968 4,965

Loss (income) from discontinued operations, net of tax - - - (575) 1

Depreciation 590 502 613 597 632

Amortization 122 321 392 162 168

Deferred income taxes (17) (224) (78) (50) (302)

Stock compensation 130 150 159 126 115

Realized excess tax benefits from stock issued under employee benefit plans (24) (34) (24) (7) (39)

Net periodic pension benefit & OPEB costs - 381 275 227 116

Business optimization charges 150 282 27 130 285

Net realized gains on Baxalta common stock - - - - (4,387)

Pension settlement charges 168 - - - -

Infusion pump & other product-related charges - - 93 (28) (18)

Loss (gain) on sale of discontinued operations - - (466) - -

Losses (gains) related to contingent payment liabilities - - 122 - -

Other net income adjustments (42) 54 269 42 264

Accounts & other current receivables, net (41) (36) (125) (4) 15

Inventories (129) (311) (439) (118) 80

Accounts payable & accrued liabilities 18 329 115 236 (197)

Business optimization & infusion pump payments (283) (125) (161) (112) (189)

Other balance sheet items 138 (103) (54) (341) 115

Net cash flows from operating activities 3,106 3,198 3,215 1,253 1,624

Capital expenditures (1,161) (1,525) (1,898) (911) (719)

Acquisitions & investments, net of cash acquired (515) (3,851) (409) (34) (48)

Divestitures & other investing activities 107 14 765 84 37

Cash flows from investing activities - continuing operations - - - (861) (730)

Cash flows from investing activities - discontinued operations - - - (946) 15

Net cash flows from investing activities (1,569) (5,362) (1,542) (1,807) (715)

Issuances of debt 1,037 3,636 41 6,868 1,641

Payments of obligations (22) (540) (1,029) (3,776) (1,381)

Debt extinguishment costs - - - - (16)

Increase (decrease) in debt with original maturities of three months or less, net (250) - 875 (575) (300)

Transfer cash & equivalents to Baxalta - - - (2,122) -

Cash dividends on common stock (804) (1,023) (1,095) (910) (268)

Proceeds & realized excess tax benefits from stock issued under employee benefit plans 512 508 369 200 325

Purchases of treasury stock (1,480) (913) (550) - (292)

Other financing activities (108) (23) (13) (42) (33)

Net cash flows from financing activities (1,115) 1,645 (1,402) (357) (324)

Effect of foreign exchange rate changes on cash & equivalents (57) (18) (79) (195) (27)

Increase (decrease) in cash & equivalents 365 (537) 192 (712) 588

Cash & equivalents at beginning of year 2,905 3,270 2,733 2,925 2,213

Cash & equivalents at end of year 3,270 2,733 2,925 2,213 2,801

Baxter International Inc.

Forecasted Cash Flow Statement

Fiscal Years Ending Dec. 31 2017E 2018E 2019E 2020E 2021E

Operating Activities:

Net income (loss) 1,066 1,158 1,224 1,332 1,453

Adjustments to reconcile net income to net cash provided by operating activities:

Add: Depreciation and amortization 567 582 608 612 593

Allowance for doubtful accounts

Changes (increases or decreases) in working capital accounts:

Increase in receivables 8 (87) (66) (90) (82)

Increase in inventories (49) (76) (58) (79) (72)

Increase in short-term deferred income taxes (8) (13) (10) (16) (18)

Increase in other prepaid expenses (16) (18) (14) (19) (17)

Increase in long-term deferred income taxes 108 (45) (32) (53) (59)

Increase in other long-term receivables (1) (9) (7) (10) (9)

Increase in other long-term assets (1) (9) (7) (9) (8)

Increase in goodwill due to acquisition of Claris Injectables (539) - - - -

Increase in accounts payable (26) 39 30 41 37

Increase in income taxes payable 77 17 13 21 23

Increase in common stock dividends payable 5 6 7 8 8

Increase in employee compensation & withholdings (32) 26 20 27 25

Increase in property, payroll & certain other taxes 10 8 6 8 7

Increase in accrued rebates (2) 11 8 11 10

Increase in other accounts payable & accrued liabilities 2 34 26 35 32

Increase in pension & other employee benefits 293 92 70 95 87

Increase in long-term deferred tax liabilities 77 15 11 17 19

Increase in other long-term liabilities (11) 5 4 5 5

Net cash provided by operating activities 1,529 1,737 1,832 1,938 2,035

Investing Activities:

Capital expenditures (714) (751) (556) (350) (365)

Capitalization of intangible assets - - - - -

Long-term debt payment - - - 294 106

Acquisition of Claris Injectables acquisition, net of goodwill (86) - - - -

Net cash used for investing activities (800) (751) (556) (56) (259)

Financing Activities:

Change in debt (3) (3) (3) (297) (403)

Increase in additional paid in capital 191 191 191 191 191

Issuance of common stock

Payment of dividends (300) (326) (354) (385) (419)

Equity component of currently redeemable convertible notes

Repurchases of common stock (625) (650) (675) (700) (750)

Change in non-controlling interest

Net cash provided by financing activities (737) (788) (842) (1,192) (1,382)

Net increase (decrease) in cash (8) 198 434 690 395

Cash, beginning of year 2,801 2,793 2,991 3,425 4,115

Cash, end of year 2,793 2,991 3,425 4,115 4,510

Baxter International Inc.

Common Size Income Statement

Fiscal Years Ending Dec. 31 2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Net sales 100% 100% 100% 100% 100% 100% 100% 100%

Cost of goods sold 47.89% 50.79% 51.69% 50.00% 49.75% 49.50% 49.25% 49.00%

Depreciation 5.72% 5.99% 6.22% 4.20% 4.26% 4.37% 4.23% 3.94%

Amortization 3.66% 1.63% 1.65% 1.35% 1.17% 1.09% 1.01% 0.94%

Gross margin 42.74% 41.59% 40.44% 44.44% 44.82% 45.04% 45.51% 46.12%

Marketing & administrative expenses 30.93% 31.04% 26.95% 25.00% 25.00% 25.00% 25.00% 25.00%

Research & development expenses 5.69% 6.05% 6.37% 6.00% 6.00% 6.00% 6.00% 6.00%

Operating income (loss) 6.12% 4.50% 7.12% 13.44% 13.82% 14.04% 14.51% 15.12%

Interest expense -1.56% -1.46% -0.88% -1.18% -1.12% -1.08% -1.03% -0.98%

Interest income 0.21% 0.20% 0.23% 0.23% 0.21% 0.21% 0.20% 0.19%

Gain related to the reduction of contingent payment liabilities 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Foreign exchange 0.07% 1.13% 0.28% 0.31% 0.31% 0.31% 0.31% 0.31%

Gain (loss) on debt extinguishment 0.00% -1.30% -1.51% 0.00% 0.00% 0.00% 0.00% 0.00%

Net realized gains on retained shares transaction 0.00% 0.00% 43.17% 0.00% 0.00% 0.00% 0.00% 0.00%

Gain on litigation settlement 0.00% 0.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Gain on sale of investments & other assets 0.19% 0.38% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00%

Other income (expense) -0.46% 0.32% 0.31% 0.10% 0.10% 0.10% 0.10% 0.10%

Income (loss) from continuing operations before income taxes 4.57% 4.29% 48.75% 12.90% 13.33% 13.58% 14.09% 14.74%

Income tax expense 0.31% 0.35% -0.12% 2.45% 2.53% 2.58% 2.68% 2.80%

Income (loss) from continuing operations 4.26% 3.94% 48.86% 10.45% 10.79% 11.00% 11.41% 11.94%

Income (loss) from discontinued operations, net of tax 19.03% 5.77% -0.01% 0.00% 0.00% 0.00% 0.00% 0.00%

Net income (loss) 23.30% 9.71% 48.85% 10.45% 10.79% 11.00% 11.41% 11.94%

Baxter International Inc.

Common Size Balance Sheet

Fiscal Years Ending Dec. 31 2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Assets:

Cash & equivalents 27.29% 22.20% 27.56% 27.38% 27.88% 30.78% 35.26% 37.07%

Accounts & other current receivables, net 17.58% 17.37% 16.64% 16.50% 16.50% 16.50% 16.50% 16.50%

Inventories 14.71% 16.09% 14.07% 14.50% 14.50% 14.50% 14.50% 14.50%

Short-term deferred income taxes 0.25% 3.03% 1.45% 1.52% 1.57% 1.60% 1.66% 1.74%

Prepaid valuation added taxes 0.66% 1.18% 1.12% 1.12% 1.06% 1.02% 0.98% 0.94%

Other prepaid expenses 3.55% 4.36% 3.36% 3.50% 3.50% 3.50% 3.50% 3.50%

Investment in Baxalta common stock - 51.65% - 0.00% 0.00% 0.00% 0.00% 0.00%

Current assets held for disposition 30.77% 2.46% 0.49% 0.49% 0.47% 0.45% 0.43% 0.41%

Total current assets 94.80% 118.34% 64.69% 65.01% 65.48% 68.35% 72.82% 74.65%

Property, plant & equipment, net 41.37% 44.00% 42.20% 44.84% 45.38% 44.37% 41.07% 38.46%

Goodwill 27.31% 26.96% 25.53% 30.73% 29.22% 28.16% 26.85% 25.76%

Other intangible assets, net 15.11% 13.53% 10.93% 9.54% 7.91% 6.53% 5.22% 4.07%

Deferred income taxes 4.95% 3.55% 6.19% 5.10% 5.27% 5.37% 5.58% 5.83%

Other long-term receivables 0.78% 1.77% 1.78% 1.78% 1.78% 1.78% 1.78% 1.78%

Non-current assets held for disposition 56.58% - - 0.00% 0.00% 0.00% 0.00% 0.00%

Other long-term assets 2.94% 2.15% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64%

Total assets 243.85% 210.29% 152.97% 158.64% 156.69% 156.21% 154.96% 152.20%

Liabilities:

Short-term debt 8.52% 17.81% - 0.00% 0.00% 0.00% 0.00% 0.00%

Current maturities of long-term debt & lease obligations 7.32% 8.13% 0.03% 0.03% 0.03% 0.03% 2.54% 3.31%

Accounts payable, principally trade 6.32% 7.18% 7.78% 7.50% 7.50% 7.50% 7.50% 7.50%

Income taxes payable 3.13% 4.54% 1.24% 1.99% 2.06% 2.10% 2.18% 2.28%

Deferred income taxes - - - - - - - -

Common stock dividends payable 3.39% 1.37% 0.69% 0.73% 0.76% 0.80% 0.83% 0.86%

Employee compensation & withholdings 4.52% 4.83% 5.33% 5.00% 5.00% 5.00% 5.00% 5.00%

Property, payroll & certain other taxes 1.72% 1.67% 1.41% 1.50% 1.50% 1.50% 1.50% 1.50%

Infusion pump reserves 1.35% 0.52% - - - - - -

Business optimization reserves 0.83% 0.98% 1.51% 1.50% 1.43% 1.37% 1.31% 1.26%

Accrued rebates 1.62% 1.93% 2.03% 2.00% 2.00% 2.00% 2.00% 2.00%

Seperation-related reserves - 1.91% 0.45% 0.45% 0.43% 0.41% 0.39% 0.38%

Other accounts payable & accrued liabilities 5.22% 6.36% 6.50% 6.50% 6.50% 6.50% 6.50% 6.50%

Current liabilites held for disposition 12.37% 0.46% 0.03% 0.03% 0.03% 0.03% 0.03% 0.02%

Total current liabilities 56.32% 57.68% 27.00% 27.24% 27.23% 27.23% 29.78% 30.61%

Long-term debt & lease obligations, net 68.39% 39.35% 27.34% 27.22% 25.86% 24.89% 21.19% 17.01%

Pension & other employee benefits 20.51% 20.48% 14.68% 17.50% 17.50% 17.50% 17.50% 17.50%

Deferred tax liabilities 1.57% 1.96% 0.92% 1.67% 1.72% 1.75% 1.82% 1.90%

Litigation reserves 0.30% 0.24% 0.19% 0.19% 0.18% 0.17% 0.16% 0.16%

Infusion pump reserves - - - 0.00% 0.00% 0.00% 0.00% 0.00%

Business optimization reserves 0.35% 0.18% 0.11% 0.11% 0.10% 0.10% 0.09% 0.09%

Contingent payment liabilities 0.48% 0.20% 0.15% 0.15% 0.14% 0.13% 0.13% 0.12%

Non-current liabilities held for disposition 15.65% - - 0.00% 0.00% 0.00% 0.00% 0.00%

Other long-term liabilities 4.20% 1.27% 1.11% 1.00% 1.00% 1.00% 1.00% 1.00%

Total liabilities 167.76% 121.36% 71.49% 75.06% 73.72% 72.78% 71.67% 68.40%

Shareholders' Equity:

Common stock & additional contributed capital 60.98% 66.06% 65.34% 66.98% 65.48% 64.82% 63.43% 62.42%

Common stock in treasury, at cost 74.57% 76.71% 78.67% -84.51% -86.43% -89.37% -91.21% -93.66%

Retained earnings 123.40% 97.14% 139.72% 145.88% 146.50% 149.02% 150.19% 152.57%

Currency translation adjustments (CTA) -21.67% -32.01% -33.83% -33.71% -32.06% -30.90% -29.46% -28.26%

Pension & other employee benefits -13.31% -10.67% -11.42% -11.38% -10.83% -10.43% -9.95% -9.54%

Hedging activities 0.32% 0.07% 0.03% 0.03% 0.03% 0.03% 0.03% 0.02%

Available-for-sale securities - 44.86% 0.39% 0.39% 0.37% 0.36% 0.34% 0.33%

Other accumulated other comprehensive income (loss) 0.62% - - 0.00% 0.00% 0.00% 0.00% 0.00%

Accumulated other comprehensive income (loss) -34.05% 2.25% -44.83% -44.67% -42.48% -40.94% -39.04% -37.45%

Total Baxter International Inc. shareholders' equity 75.75% 88.74% 81.57% 252.70% 255.93% 262.27% 265.79% 271.20%

Noncontrolling interests 0.34% 0.19% -0.10% -0.10% -0.09% -0.09% -0.09% -0.08%

Total equity 76.09% 88.93% 81.47% 252.61% 255.84% 262.18% 265.71% 271.12%

Total liabilities and shareholders' equity 243.85% 210.29% 152.97% 327.66% 329.56% 334.96% 337.38% 339.51%

Baxter International Inc.

Value Driver Estimation

Fiscal Years Ending Dec. 31 2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Net Operating Profit Less Adjusted Taxes (NOPLAT) 684 389 1,365 1,281 1,152 1,229 1,316 1,429

Invested Capital (IC) 14,672 13,348 7,569 7,735 7,955 7,938 7,727 7,539

Return on Invested Capital (ROIC) 4.92% 2.65% 10.23% 16.93% 14.90% 15.45% 16.58% 18.49%

Free Cash Flow (FCF) (92) 1,714 7,144 1,115 933 1,246 1,526 1,617

Economic Profit (EP) (204) (548) 513 798 658 721 809 935

Tax Rates

Statutory Rate 6.97% 15.50% 34.90% 21.31% 21.31% 21.31% 21.31% 21.31%

+ Retained shares tax free exchange gains 0.00% 0.00% -31.96% 0.00% 0.00% 0.00% 0.00% 0.00%

+ State Taxes, net of Federal Benefit -0.96% -1.34% 0.02% -0.76% -0.76% -0.76% -0.76% -0.76%

+Foreign Earnings at Different Rates -0.64% 1.14% 0.10% -1.56% -1.56% -1.56% -1.56% -1.56%

Marginal Tax Rate 5.37% 15.30% 3.06% 19.00% 19.00% 19.00% 19.00% 19.00%

Calculating NOPLAT

Operating Revenues 10,719 9,968 10,163 10,200 10,725 11,128 11,671 12,166

-Cost of Goods Sold 5,133 5,063 5,253 5,100 5,336 5,508 5,748 5,962

-Depreciation 613 597 632 429 457 487 494 479

-Amortization of Non-Goodwill Intangibles 392 162 168 138 125 121 118 114

-Marketing & Administrative Expenses 3,315 3,094 2,739 2,550 2,681 2,782 2,918 3,042

-Research and Development Expenses 610 603 647 612 644 668 700 730

+Implied Interest on Operating Leases 40 39 27 24 23 23 22 21

Adjusted EBITA 696 488 751 1,395 1,506 1,585 1,715 1,861

Adjusted Taxes

Income Tax Provision 33 35 (12) 250 271 287 312 341

Add: Tax Shield on Interest Expense 32 28 17 23 23 23 23 23

Add: Tax on Implied Lease Interest 8 7 5 5 4 4 4 4

Add: Tax Shield on Amortized Goodwill 74 31 32 26 24 23 22 22

Add: Tax Shield on Loss on Debt Extinguishment - (25) (29) - - - - -

Less: Tax on Gain related to the reduction of contingent payment liabilities - - - - - - - -

Less: Tax on Foreign Exchange Gain 2 21 5 6 6 7 7 7

Less: Tax on Net realized gains on retained shares transaction - - 833 - - - - -

Less: Tax on Gain on litigation settlement - 10 - - - - - -

Less: Tax on Gain on sale of investments & other assets 4 7 1 - - - - -

Less: Tax on Other income (9) 6 6 2 2 2 2 2

Less: Tax on Interest (or Investment) Income 4 4 4 4 4 4 4 4

Adjusted Taxes 147 28 (837) 291 310 324 348 375

Plus: Change in Deferred Tax Assets/Liabilities

Current Year Deferred Tax Assets 558 656 776 676 734 776 844 921

Current Year Deferred Tax Liabilities 168 195 93 170 184 195 212 231

Previous Year Deferred Tax Assets 545 558 656 776 676 734 776 844

Previous Year Deferred Tax Liabilities 21 168 195 93 170 184 195 212

Change in Deferred Taxes 134 (71) (222) 177 (44) (31) (51) (57)

EBITA 696 488 751 1,395 1,506 1,585 1,715 1,861

-Adjusted Taxes 147 28 (837) 291 310 324 348 375

+Change in Deferred Taxes (t-1) 134 (71) (222) 177 (44) (31) (51) (57)

NOPLAT 684 389 1,365 1,281 1,152 1,229 1,316 1,429

Invested Capital Computation

Operating Current Assets:

Normal Cash (5% of Sales) 322 299 305 306 322 334 350 365

Accounts Receivable, Net 1,884 1,731 1,691 1,683 1,770 1,836 1,926 2,007

Inventory 1,577 1,604 1,430 1,479 1,555 1,613 1,692 1,764

Prepaid Valuation Added Taxes 71 118 114 114 114 114 114 114

Other Prepaid Expenses 380 435 341 357 375 389 408 426

Investment in Baxalta Common Stock - 5,148 - - - - - -

Current Assets Held for Disposition 3,298 245 50 50 50 50 50 50

Total Operating Current Assets 7,532 9,580 3,931 3,989 4,186 4,337 4,541 4,726

Baxter International Inc.

Value Driver Estimation

Fiscal Years Ending Dec. 31 2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Operating Current Liabilities:

Accounts Payable 677 716 791 765 804 835 875 912

Income Taxes Payable 336 453 126 203 221 233 254 277

Common Stock Dividends Payable 363 137 70 75 81 89 96 105

Employee Compensation & Withholdings 485 481 542 510 536 556 584 608

Property, Payroll, & Certain Other Taxes 184 166 143 153 161 167 175 182

Accrued Rebates 174 192 206 204 215 223 233 243

Current Liabilities Held for Disposition 1,326 46 3 3 3 3 3 3

Other 560 634 661 663 697 723 759 791

Total Operating Current Liabilities 4,105 2,825 2,542 2,576 2,718 2,828 2,979 3,122

Total Operating Current Assets 7,532 9,580 3,931 3,989 4,186 4,337 4,541 4,726

Less: Total Operating Current Liabilities 4,105 2,825 2,542 2,576 2,718 2,828 2,979 3,122

Net Operating Working Capital 3,427 6,755 1,389 1,413 1,468 1,508 1,562 1,604

Net PPE 4,434 4,386 4,289 4,574 4,867 4,937 4,794 4,679

Other Operating Assets

Other Intangible Assets, Net 1,620 1,349 1,111 973 848 727 609 495

Other Long-term Receivables 84 176 181 182 191 198 208 217

Non-current Assets Held for Disposition 6,065 - - - - - - -

Other Long-term Assets 315 214 167 168 176 183 192 200

PV of Operating Leases 906 615 560 543 527 511 496 481

Other Operating Assets 8,990 2,354 2,019 1,865 1,742 1,619 1,504 1,392

Other Operating Liabilities

Contingent Payment Liabilities 51 20 15 15 15 15 15 15

Non-current Liabilities Held for Disposition 1,677 - - - - - - -

Other Long-term Liabilities 450 127 113 102 107 111 117 122

Other Operating Liabilities 2,178 147 128 117 122 126 132 137

Invested Capital:

Add: Net Operating Working Capital 3,427 6,755 1,389 1,413 1,468 1,508 1,562 1,604

Add: Net PPE 4,434 4,386 4,289 4,574 4,867 4,937 4,794 4,679

Add: Other Operating Assets 8,990 2,354 2,019 1,865 1,742 1,619 1,504 1,392

Less: Other Operating Liabilities 2,178 147 128 117 122 126 132 137

Total Invested Capital 14,672 13,348 7,569 7,735 7,955 7,938 7,727 7,539

Return on Invested Capital

NOPLAT / 684 389 1,365 1,281 1,152 1,229 1,316 1,429

Beginning Invested Capital 13,896 14,672 13,348 7,569 7,735 7,955 7,938 7,727

ROIC 4.92% 2.65% 10.23% 16.93% 14.90% 15.45% 16.58% 18.49%

Economic Profit

Beginning Invested Capital 13,896 14,672 13,348 7,569 7,735 7,955 7,938 7,727

ROIC 4.92% 2.65% 10.23% 16.93% 14.90% 15.45% 16.58% 18.49%

WACC 6.39% 6.39% 6.39% 6.39% 6.39% 6.39% 6.39% 6.39%

EP (Beg IC * (ROIC - WACC)) -204 -548 513 798 658 721 809 935

FCF

NOPLAT 684 389 1,365 1,281 1,152 1,229 1,316 1,429

Add: Beg Invested Capital 13,896 14,672 13,348 7,569 7,735 7,955 7,938 7,727

Less: Current Invested Capital 14,672 13,348 7,569 7,735 7,955 7,938 7,727 7,539

FCF (92) 1,714 7,144 1,115 933 1,246 1,526 1,617

Baxter International Inc.

Weighted Average Cost of Capital (WACC) Estimation

WACC 6.39%

Cost of Equity 6.73%

Cost of Debt 4.32%

Cost of Preferred Stock -$

Market Value of Equity (Millions) 28,453$

Market Value of Total Debt (Millions) 3,342$

Market Value of Preferred Stock -$

Market Value of Firm 31,795$

Marginal Tax Rate 19.00%

Equations:

Equity Market Risk Premium 4.80%

x Beta 0.81

+ Risk-free Rate 2.84%

Cost of Equity 6.73%

Shares Outstanding (Millions) 540

x Current Price 52.73$

Equity Value 28,453$

Total Value of Equity 28,453$

Long-term Debt, net 2,779$

Current portion of Long-term Debt 3$

PV of Operating Leases 560$

Value of Total Debt 3,342$

Baxter International Inc.

Discounted Cash Flow (DCF) and Economic Profit (EP) Valuation Models

Key Inputs:

CV Growth 2.50%

CV ROIC 18.49%

WACC 6.39%

Cost of Equity 6.73%

Fiscal Years Ending Dec. 31 2017E 2018E 2019E 2020E 2021E

DCF Model

Discount Period 1 2 3 4 5

NOPLAT 1,281 1,152 1,229 1,316 1,429

Beginning IC 7,569 7,735 7,955 7,938 7,727

Ending IC 7,735 7,955 7,938 7,727 7,539

∆ in Invested Capital 167 220 (17) (211) (188)

NOPLAT 1,281 1,152 1,229 1,316 1,429

Less: ∆ in Invested Capital (167) (220) 17 211 188

Free Cash Flow 1,115 933 1,246 1,526 1,617

Continuing Value 31,781

PV of Continuing Value 24,808

PV of Free Cash Flows 1,048 824 1,035 1,191

Value of Operations 28,906

+ Excess Cash 2,496

- Total Debt (2,779)

- PV of Operating Leases (560)

- Employee Stock Option Plan (689)

- Reserve Accounts (229)

- Pension & Other Employee Benefits (1,492)

- Noncontrolling interest 10

Value of Equity 25,663

Shares Outstanding 540

Intrinsic Value (per share) 2016 FYE 47.56

Price Today 4/19/17 48.36

EP Model

Periods to Discount 1 2 3 4 5

Economic Profit 798 658 721 809 935

Continuing Value 24,053

PV of Terminal Year EP 18,776

PV of Economic Profit 750 581 599 631

Sum of EP 21,337

Add: Beginning Invested CapitalCV 7,569

Value of Operations 28,906

+ Excess Cash 2,496

- Total Debt (2,779)

- PV of Operating Leases (560)

- Employee Stock Option Plan (689)

- Reserve Accounts (229)

- Pension & Other Employee Benefits (1,492)

- Noncontrolling interest 10

Value of Equity 25,663

Shares Outstanding 540

Intrinsic Value (per share) 2016 FYE 47.56

Price Today 4/19/17 48.36

Baxter International Inc.

Dividend Discount Model (DDM) or Fundamental P/E Valuation Model

Fiscal Years Ending Dec. 31 2017E 2018E 2019E 2020E 2021E

EPS 2.00$ 2.20$ 2.35$ 2.58$ 2.85$

Key Assumptions

CV growth 2.50%

CV ROE 14.94%

Cost of Equity 6.73%

Future Cash Flows

P/E Multiple (CV Year) 19.69

EPS (CV Year) 2.85$

Future Stock Price 56.12$

Dividends Per Share 0.56$ 0.61$ 0.67$ 0.74$

Future Cash Flows 0.56$ 0.61$ 0.67$ 0.74$ 56.12$

Periods 1 2 3 4 4

Discounted Cash Flows 0.52$ 0.54$ 0.55$ 0.57$ 43.25$

Intrinsic Value FYE 2016 44.91$

Price Today 4/19/17 45.54$

Baxter International Inc.

Relative Valuation Models

EPS EPS

Ticker Company Price 2017E 2018E P/E 17 P/E 18

PFE Pfizer Inc. 33.84 $2.55 $2.78 13.3 12.2

ABT Abbott Laboratories 43.43 $2.45 $2.75 17.7 15.8

MDT Medtronic plc 80.33 $4.58 $4.96 17.5 16.2

BDX Becton, Dickinson, and Co. 183.38 $9.44 $10.40 19.4 17.6

Average 17.0 15.4

BAX Baxter International Inc. $52.73 2.00 2.20 26.4 24.0

Implied Value:

Relative P/E (EPS16) $ 33.97

Relative P/E (EPS17) 33.94$

Baxter International

Baxter International Inc.

Key Management Ratios

Fiscal Years Ending Dec. 31 2014 2015 2016 2017E 2018E 2019E 2020E 2021E

Liquidity Ratios

Current Ratio (Current Assets/Current Liabilities) 1.68 2.05 2.40 2.39 2.40 2.51 2.45 2.44

Operating Cash Flow Ratio (Operating CF/Current Liabilities) 0.53 0.22 0.59 0.55 0.59 0.60 0.56 0.55

Quick Ratio (Current Assets - Inventories)/Current Liabilities 1.42 1.77 1.87 1.85 1.87 1.98 1.96 1.97

Activity or Asset-Management Ratios

Asset Turnover Ratio (Sales/Total Assets) 0.41 0.48 0.65 0.63 0.64 0.64 0.65 0.66

Inventory Turnover Ratio (Sales/Total Inventory) 6.80 6.21 7.11 6.90 6.90 6.90 6.90 6.90

Receivables Turnover Ratio (Sales/Average Accts. Receivable) 4.47 5.51 5.94 6.05 6.21 6.17 6.21 6.19

Financial Leverage Ratios

Debt to Equity Ratio (Total Debt/Total Equity) 1.11 0.73 0.34 0.33 0.31 0.30 0.28 0.24

Equity Ratio (Shareholders' Equity/Total Assets) 0.31 0.42 0.53 0.53 0.53 0.53 0.54 0.55

Interest Coverage (EBIT/Interest Expense) 3.93 3.08 8.13 11.42 12.36 13.04 14.15 15.39

Profitability Ratios

Return on Assets (Net Income/Total Assets) 9.55% 4.62% 31.94% 6.59% 6.89% 7.04% 7.37% 7.84%

Return on Equity (Net Income/Shareholders' Equity) 30.62% 10.92% 59.96% 12.50% 13.01% 13.18% 13.70% 14.25%

Gross Margin (Revenue - COGS)/Revenue 52.11% 49.21% 48.31% 50.00% 50.25% 50.50% 50.75% 51.00%

EBIT Margin (EBIT/Sales) 6.12% 4.50% 7.12% 13.44% 13.82% 14.04% 14.51% 15.12%

Profit Margin (Net Income/Sales) 23.30% 9.71% 48.85% 10.45% 10.79% 11.00% 11.41% 11.94%

Payout Policy Ratios

Dividend Payout Ratio (Dividends Paid/Net Income) 43.85% 94.01% 5.40% 28.12% 28.14% 28.94% 28.92% 28.86%

Total Payout Ratio (Dividends Paid + Repurchases)/Net Income 65.88% 94.01% 11.28% 86.76% 84.28% 84.09% 81.46% 80.49%

Present Value of Operating Lease Obligations (2016) Present Value of Operating Lease Obligations (2015) Present Value of Operating Lease Obligations (2014)

Operating Operating Operating

Fiscal Years Ending Dec. 31 Leases Fiscal Years Ending Dec. 31 Leases Fiscal Years Ending Dec. 31 Leases

2017 129 2016 149 2015 222

2018 108 2017 125 2016 187

2019 85 2018 106 2017 163

2020 67 2019 86 2018 130

2021 58 2020 72 2019 113

Thereafter 216 Thereafter 176 Thereafter 232

Total Minimum Payments 663 Total Minimum Payments 714 Total Minimum Payments 1047

Less: Interest 103 Less: Interest 99 Less: Interest 141

PV of Minimum Payments 560 PV of Minimum Payments 615 PV of Minimum Payments 906

Capitalization of Operating Leases Capitalization of Operating Leases Capitalization of Operating Leases

Pre-Tax Cost of Debt 4.32% Pre-Tax Cost of Debt 4.32% Pre-Tax Cost of Debt 4.32%

Number Years Implied by Year 6 Payment 3.7 Number Years Implied by Year 6 Payment 2.4 Number Years Implied by Year 6 Payment 2.1

Lease PV Lease Lease PV Lease Lease PV Lease

Year Commitment Payment Year Commitment Payment Year Commitment Payment

1 129 123.7 1 149 142.8 1 222 212.8

2 108 99.2 2 125 114.9 2 187 171.8

3 85 74.9 3 106 93.4 3 163 143.6

4 67 56.6 4 86 72.6 4 130 109.8

5 58 47.0 5 72 58.3 5 113 91.5

6 & beyond 58 158.4 6 & beyond 72 132.5 6 & beyond 113 176.1

PV of Minimum Payments 559.7 PV of Minimum Payments 614.5 PV of Minimum Payments 905.6

Baxter International

Effects of ESOP Exercise and Share Repurchases on Common Stock Balance Sheet Account and Number of Shares Outstanding

Number of Options Outstanding (shares): 33

Average Time to Maturity (years): 6.20

Expected Annual Number of Options Exercised: 5

Current Average Strike Price: 35.73$

Cost of Equity: 6.73%

Current Stock Price: $52.73

2017E 2018E 2019E 2020E 2021E

Increase in Shares Outstanding: 5 5 5 5 5

Average Strike Price: 35.73$ 35.73$ 35.73$ 35.73$ 35.73$

Increase in Common Stock Account: 191 191 191 191 191

Change in Treasury Stock 625 650 675 700 750

Expected Price of Repurchased Shares: 52.73$ 56.28$ 60.06$ 64.11$ 68.42$

Number of Shares Repurchased: 12 12 11 11 11

Shares Outstanding (beginning of the year) 540 533 527 521 515

Plus: Shares Issued Through ESOP 5 5 5 5 5

Less: Shares Repurchased in Treasury 12 12 11 11 11

Shares Outstanding (end of the year) 533 527 521 515 510

VALUATION OF OPTIONS GRANTED IN ESOP

Ticker Symbol BAX

Current Stock Price $52.73

Risk Free Rate 2.84%

Current Dividend Yield 0.98%

Annualized St. Dev. of Stock Returns 18.32%

Average Average B-S Value

Range of Number Exercise Remaining Option of Options

Outstanding Options of Shares Price Life (yrs) Price Granted

Range 1 33 35.73 6.20 20.83$ 689$

Total 33 35.73$ 6.20 20.83$ 689$

Baxter International

Sensitivity Analysis

48.36 6.00% 6.39% 7.00% 7.50% 8.00%

1.5% 45.24 41.12 35.82 32.29 29.30

2.0% 49.24 44.33 38.14 34.10 30.74

2.5% 54.38 48.36 40.98 36.28 32.44

3.0% 61.25 53.58 44.52 38.95 34.48

3.5% 70.85 60.61 49.08 42.27 36.98

48.36 15.0% 17.0% 19.0% 21.0% 23.0%

8.0% 53.96 52.07 50.18 48.27 46.35

9.0% 52.96 51.10 49.23 47.35 45.46

10.0% 52.05 50.21 48.36 46.50 44.63

11.0% 51.21 49.39 47.56 45.71 43.87

12.0% 50.45 48.64 46.83 45.00 43.16

48.36 4.0% 5.0% 6.0% 7.0% 8.0%

2.0% 51.87 50.86 49.84 48.83 47.82

3.0% 51.40 50.39 49.37 48.36 47.35

4.0% 50.93 49.92 48.90 47.89 46.88

5.0% 50.46 49.45 48.43 47.42 46.41

6.0% 49.99 48.98 47.96 46.95 45.94

48.36 5.0% 10.0% 15.0% 20.0% 25.0%

0.71 54.91 55.03 55.16 55.29 55.44

0.81 48.26 48.36 48.47 48.59 48.72

0.91 42.92 43.01 43.11 43.22 43.33

1.01 38.55 38.63 38.72 38.82 38.92

1.11 34.90 34.98 35.06 35.14 35.24

48.36 4.60% 4.70% 4.80% 4.90% 5.00%

14.50% 48.34 47.33 46.35 45.41 44.50

16.50% 49.52 48.48 47.48 46.51 45.58

18.49% 50.44 49.38 48.36 47.38 46.43

20.50% 51.19 50.11 49.08 48.08 47.12

22.50% 51.80 50.71 49.66 48.65 47.68

Injectables Growth Rate

3-y

ear

Be

ta

Market Risk Premium

CV

RO

IC

WACC

CV

of

Gro

wth

Marginal Tax Rate

Dep

reci

atio

n R

ate

Short-term Capex as % of Sales

Lon

g-te

rm C

apex


Recommended